News Archive

26 Jan. 2017

Biomay AG reports positive results from a second Phase IIb trial with the innovative 3rd generation grass pollen allergy vaccine BM32

Biomay, a global leader in allergy immunotherapy, announced today that a second phase IIb study (clinicaltrials.gov identifier NCT02643641) has been successfully completed with its third generation grass pollen allergy vaccine...[more]

6 Dec. 2016

Biomay Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award

Biomay announces that the company has been named one of the winners of the Corporate LiveWire 2016 Healthcare and Life Sciences Awards in the category Best in Allergy Therapeutics Developments. "We are delighted that our...[more]

4 Feb. 2016

Biomay has been granted U.S. patent for peptide carrier fusion allergy vaccines

Biomay announced today that the company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the composition and use of allergy vaccines based on its innovative...[more]

28 Jan. 2016

Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32

Biomay announced today that a new phase II trial with its innovative grass pollen allergy vaccine BM32 based on the proprietary peptide carrier protein platform has been initiated. The aim of the study is the optimization of...[more]

3 Sep. 2015

Fresenius Medical Care releases new adsorber IgEnio® in Europe for treatment of severe allergic symptoms

Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market. Latest epidemiological data shows that IgE-mediated diseases affect more than 25...[more]

3 Jun. 2015

Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference

Biomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona,...[more]

28 Jan. 2015

Biomay AG reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32

Biomay, a global leader in allergy immunotherapy, announced today that a landmark phase IIb study (clinicaltrials.gov identifier NCT1538979) has been successfully completed with its 3rd generation grass pollen allergy vaccine...[more]

4 Sep. 2014

Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding...[more]

16 Dec. 2013

Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32

Biomay announced today that an interim analysis for futility has been successfully completed for an ongoing phase IIb study (clinicaltrials.gov identifier NCT01538979) with its 3rd generation grass pollen allergy vaccine BM32....[more]

19 Nov. 2013

Biomay adds new recombinant allergens to its product offering

Biomay announces today that the company is broadening its offering of recombinant allergens. Effective immediately we make the major ragweed allergen Amb a 1 as well as the new and important house dust mite allergen Der p 23...[more]

Displaying 1 to 10 of 36
<< First < Previous 1-10 11-20 21-30 31-36 Next > Last >>

Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com